Forty Seven
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Forty Seven and buy or sell other stocks, ETFs, and their options commission-free!About FTSV
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities.
CEOMark A. McCamish, MD, PhD
CEOMark A. McCamish, MD, PhD
Employees—
Employees—
HeadquartersMenlo Park, California
HeadquartersMenlo Park, California
Founded2014
Founded2014
Employees—
Employees—
FTSV Key Statistics
Market cap4.60B
Market cap4.60B
Price-Earnings ratio-38.73
Price-Earnings ratio-38.73
Dividend yield—
Dividend yield—
Average volume1.26M
Average volume1.26M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$95.52
52 Week high$95.52
52 Week low$5.53
52 Week low$5.53
Stock Snapshot
The current Forty Seven(FTSV) stock price is $95.51, with a market capitalization of 4.6B. The stock trades at a price-to-earnings (P/E) ratio of -38.73.
On 2025-11-05, Forty Seven(FTSV) stock opened at —, reached a high of —, and a low of —.
Forty Seven(FTSV) shares are trading with a volume of 0, against a daily average of 1.26M.
In the last year, Forty Seven(FTSV) shares hit a 52-week high of $95.52 and a 52-week low of $5.53.
In the last year, Forty Seven(FTSV) shares hit a 52-week high of $95.52 and a 52-week low of $5.53.